FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Uber Limits Staff Use of AI Tools to Cut Costs

By

Uber Technologies (UBER) has placed usage caps on some AI-powered coding tools used by its staff to control costs after the company exceeded its AI budget earlier this year, Bloomberg reported Tuesday, citing a company spokesperson.

All Uber employees are limited to $1,500 per month in token spending per AI coding tool, the spokesperson reportedly told Bloomberg.

Uber didn't immediately reply to requests for comment from.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $71.75, Change: $-2.02, Percent Change: -2.74%

Related Articles

Wire

Uber Limits Staff Usage of AI Tools to Cut Costs, Bloomberg Reports

Uber Limits Staff Usage of AI Tools to Cut Costs, Bloomberg Reports

$AMZN$UBER
Wire

Truist Securities Adjusts Dollar General Price Target to $114 From $109, Maintains Hold Rating

Dollar General (DG) has an average rating of Hold and mean price target of $137.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $108.66, Change: $-1.27, Percent Change: -1.16%

$DG
Wire

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy.The biotechnology company said estimated glomerular filtration rate results from the trial are now expected in Q3. Pending those results, Vera plans to submit a supplemental biologics license application for full approval in Q4.Vera said the FDA alignment was supported by phase 2b Origin trial results showing significant reductions in proteinuria, stabilization of kidney function and a placebo-comparable safety profile, while its phase 3 Origin trial met its primary endpoint and remains ongoing to evaluate eGFR changes.Atacicept has received FDA Breakthrough Therapy Designation for IgAN, and Vera is also studying the drug in other kidney diseases, with enrollment completed in a separate dose-ranging study, the company said.Shares of Vera Therapeutics were down more than 6% in Tuesday trading.Price: $31.76, Change: $-2.18, Percent Change: -6.42%

$VERA